Welcome to our dedicated page for Indaptus Therapeutics SEC filings (Ticker: INDP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Indaptus Therapeutics, Inc. (Nasdaq: INDP) SEC filings page on Stock Titan provides structured access to the company’s regulatory documents as filed with the U.S. Securities and Exchange Commission. As a clinical-stage biotechnology issuer incorporated in Delaware and listed on the Nasdaq Capital Market, Indaptus uses its SEC reports to describe the development of its Decoy bacterial immunotherapy platform, its clinical programs, and its financing and corporate activities.
Through Forms 10-K and 10-Q, investors can review detailed discussions of Indaptus’ business, including its focus on Decoy20 and related product candidates for cancer and viral infections, pre-clinical data summaries, risk factors, and management’s analysis of research and development and general and administrative expenses. Current reports on Form 8-K capture material events such as the launch and progression of the INDP-D101 clinical trial, reverse stock split implementation, private placements of convertible promissory notes and warrants, standby equity purchase agreements, preferred stock financings, and changes to the board of directors and executive leadership.
Registration statements on Form S-1 and amendments (S-1/A) outline the terms of securities offerings, including common stock, pre-funded warrants, common warrants and placement agent warrants, as well as estimated offering expenses and recent sales of unregistered securities. These filings also confirm Indaptus’ status as a smaller reporting company and non-accelerated filer and provide information on its incorporation and principal executive offices.
On Stock Titan, users can access these filings alongside AI-powered summaries that highlight key points such as capital structure changes, potential dilution from convertible instruments and warrants, and the implications of preferred stock transactions. The platform also surfaces insider-related disclosures and board changes reported in 8-Ks, helping readers quickly identify governance developments. Real-time updates from EDGAR ensure that new Indaptus filings, from quarterly earnings reports to material event disclosures, are added promptly, while AI-generated explanations help interpret complex prospectus language, financing terms and clinical program descriptions within the filings.
Indaptus Therapeutics, Inc. — Amendment No. 1 to a Schedule 13G/A filed by YA II PN, Ltd. states that the reporting group beneficially owns 0 shares of Common Stock, representing 0% of the class as of 12/31/2025. The filing lists affiliated entities (YA Global Investments II (U.S.), Yorkville Advisors Global, YAII GP entities, SC-Sigma, and Mark Angelo) and explains their relationships and potential attribution. The amendment is signed and dated 04/06/2026.
Indaptus Therapeutics, Inc. reported leadership and board changes. Chief Financial Officer Nir Sassi resigned effective April 1, 2026, and the company stated his resignation was not due to any disagreement regarding operations, policies, or practices.
On March 31, 2026, the board appointed Qinglai Lu, 48, as a director effective April 8, 2026 and determined he qualifies as an independent director under Nasdaq rules. The board also appointed Yu Ding, 51, as Chief Financial Officer effective April 1, 2026 after reviewing his qualifications.
The company adjusted its audit committee, with Matthew McMurdo resigning and Qinglai Lu and Jerome Jabbour joining the committee on March 31, 2026.
Indaptus Therapeutics, Inc. reported that investor Yun Yao is a more than 10% owner with 41,991,000 shares of common stock. These shares arose from a securities purchase agreement under which Yao acquired Series AA and Series AAA Convertible Non-Redeemable Preferred Stock and then converted all of it into common shares following the closing on March 23, 2026.
SINO LION VENTURES Ltd has become a major shareholder of Indaptus Therapeutics, Inc. by converting preferred stock into common shares. On March 19, 2026, it agreed to acquire 259,300 shares of Series AAA Convertible Non-Redeemable Preferred Stock from David Elliot Lazar. Each preferred share is convertible into 150 shares of common stock. After the transaction closed on March 23, 2026, SINO LION VENTURES Ltd submitted a notice of conversion for all of its Series AAA Preferred Stock, resulting in the issuance of 38,895,000 shares of common stock, which it now holds directly as reported on this initial Form 3. A footnote states these securities may also be deemed beneficially owned by Chenhao Xu, who disclaims beneficial ownership except for any pecuniary interest.
Indaptus Therapeutics Chief Executive Officer Junyi Dai reported ownership of 11,250,000 shares of common stock. This position reflects the full conversion of 75,000 shares of Series AAA Convertible Non-Redeemable Preferred Stock, which were acquired under a securities purchase agreement and then immediately converted after closing.
Indaptus Therapeutics, Inc. (INDP) disclosed a new investor group led by Yun Yao acquiring and converting preferred stock into a large common equity position. The group bought Series AA and Series AAA Preferred Stock for an aggregate $11,200,000 under a Securities Purchase Agreement signed on March 19, 2026.
Following conversion on March 24, 2026, Yun Yao beneficially owns 41,991,000 common shares, or 37.8% of the class, Sino Lion Ventures Limited and its controller Chenhao Xu each report 38,895,000 shares, or 35.0% each, while Junyi Dai and Ting Yang each hold 11,250,000 shares, or 10.1%, and Lina Deng holds 5,550,000 shares, or 5.0%. All percentages are based on 111,178,324 common shares outstanding as of March 30, 2026, after giving effect to the conversion.
The filing notes the Reporting Persons may be deemed a “group” solely for purposes of the Purchase Agreement and related transactions, and they collectively may be deemed to share beneficial ownership of 108,936,000 common shares, while each disclaims beneficial ownership of others’ shares beyond their pecuniary interest. In connection with the closing on March 23, 2026, Junyi Dai was appointed Chief Executive Officer and a director, signaling an aligned management and ownership shift.
Indaptus Therapeutics reported a change in control tied to earlier issuances of Series AA and Series AAA Convertible Preferred Stock. David Lazar had purchased 300,000 Series AA and 700,000 Series AAA shares, which are convertible into a combined 111,000,000 shares of common stock. He has now sold all 700,000 Series AAA shares and rights to 196,800 Series AA shares to five Purchasers for an aggregate $11.2 million. Based on full conversion of all Preferred Stock and a total of 113,242,324 common shares outstanding on that basis, the Purchasers together would beneficially own about 96.20% of the common stock, while Lazar would hold about 1.82%. Several directors, including co-CEO Jeffrey Meckler, resigned, and Lazar stepped down as co-CEO and Chairman while remaining on the board. The board appointed Junyi Dai as Chairman effective March 18, 2026 and as Chief Executive Officer effective at closing of the March 2026 share sale.
Indaptus Therapeutics’ major shareholder David E. Lazar has sharply reduced his economic stake and stepped down as co‑Chief Executive Officer while remaining on the Board. He entered a March 2026 securities purchase agreement to sell 700,000 shares of Series AAA Preferred Stock and 196,800 shares of Series AA Preferred Stock for an aggregate $11,200,000.
These preferred shares are convertible into a total of 108,936,000 common shares. After closing on March 23, 2026, Lazar retains 103,200 Series AA Preferred shares, convertible into 2,064,000 common shares. Based on 2,242,324 common shares outstanding as of March 16, 2026 plus his remaining convertibles, the filing reports beneficial ownership of approximately 47.93%, which would drop to about 1.82% after other purchasers convert their preferred stock.
Indaptus Therapeutics director David E. Lazar sold a large block of the company’s convertible preferred stock. On March 23, 2026, he completed a Securities Purchase Agreement under which he sold all 700,000 shares of Series AAA Preferred Stock, which were convertible into 105,000,000 shares of common stock, and 196,800 shares of Series AA Preferred Stock, which were convertible into 3,936,000 shares of common stock. Following this transaction, he retained 103,200 shares of Series AA Preferred Stock, convertible into 2,064,000 shares of common stock. Both the Series AA and Series AAA Preferred Stock are perpetual and convertible at the holder’s option for no additional consideration.
Indaptus Therapeutics reports a transformative year marked by a recapitalization, governance changes and a halt to clinical development. On December 22, 2025 it sold 300,000 Series AA and 700,000 Series AAA preferred shares to David E. Lazar for $6.0 million, each share priced at $6.00. These series are convertible into a combined 111,000,000 common shares, and Mr. Lazar is now the beneficial owner of about 96.4% of the company’s common stock on an as-converted, fully diluted basis.
Stockholders approved a large increase in authorized common shares to 1,000,000,000, a reverse stock split range, and board changes that installed multiple Lazar designees. The company repriced roughly 1.68 million warrants to an exercise price of $1.75 per share and used ATM sales, a $5.7 million convertible note, equity lines and several 2024–2025 equity/warrant financings to raise cash.
Indaptus, a clinical-stage immunotherapy developer, discontinued enrollment in its Decoy20 monotherapy and combination trials and has no current plans to start new clinical studies. It discloses substantial doubt about its ability to continue as a going concern and is evaluating a strategic transaction to invest in or acquire a target company.